What is the 13F Pro Quality Score for LLY?

13F Pro ranks ELI LILLY & Co (LLY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LLY's current score at https://13fpro.ai/research/LLY (free sign-up required for the full ranking).

Which hedge funds own the most LLY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LLY include LILLY ENDOWMENT, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LLY as soon as new 13F filings post.

Where does 13F Pro source LLY data?

All ELI LILLY & Co fundamentals and ownership data come directly from SEC EDGAR. ELI LILLY & Co files with the SEC under CIK 59478. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LLY in?

ELI LILLY & Co (LLY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives LLY's revenue?

Per ELI LILLY & Co's latest 10-Q filed with the SEC on 2026-04-30, the biggest revenue drivers are: Oncology ($2.3B, +16% YoY); Immunology ($1.2B, +10% YoY); Collaboration and Other Revenue ($1.3B, +19% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/LLY.

What are LLY's largest expenses?

ELI LILLY & Co's latest 10-Q reports these as the largest expense items: Cost of sales ($3.6B, +61% YoY); Research and development ($3.5B, +28% YoY); Marketing, selling, and administrative ($2.9B, +19% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is LLY research updated on 13F Pro?

LLY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ELI LILLY & Co(LLY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 59478 LLY stock profile & AI dashboard →

13F Pro Quality Score

89.3/100

Rank #2 of 2,879 stocksTOP 1%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.5/100

Profitability

92.7/100

Balance Sheet

96.3/100

Earnings Quality

92.6/100

Free Cash Flow

85.2/100

Institutional Flow

64.4/100

Revenue Scale

98.0/100

Dilution Risk

57.9/100

LLY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ELI LILLY & Co (LLY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LLY at 89.3/100 on a 32-signal composite quality model, placing it at rank #2 of 2,879 stocks — the top 1% of the AI-ranked universe. LLY scores in the top quartile across revenue scale (98.0), balance sheet strength (96.3), profitability (92.7). Based on the latest XBRL financial filings (Q1 2026), ELI LILLY & Co reports quarterly revenue of $19.8B, net income of $7.4B, an operating margin of 44.7%. Top institutional holders of LLY by reported 13-F value include LILLY ENDOWMENT, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LLY trades on the NYSE exchange and files with the SEC under CIK 59478. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LLY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ELI LILLY & Co directly from SEC EDGAR. ELI LILLY & Co's 13F Pro composite quality score has ranged between 67 and 90 since 2021, currently 89.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ELI LILLY & Co

Quirks, history, and lore behind LLY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. pharmaceutical company · mega-cap · listed on the NYSE · headquartered in Indiana.
2
The Numbers
Annual revenue surpassed $40 billion in recent years, and its market cap rocketed past $700 billion — making it one of the most valuable healthcare companies on Earth.
3
The History
Founded in 1876 by a Civil War veteran-turned-chemist, it was among the first drug companies to mass-produce insulin in the 1920s, partnering with the scientists who discovered it.
4
The Secret
It quietly became a neuroscience and oncology powerhouse, with blockbuster drugs treating everything from diabetes to cancer to Alzheimer's driving its explosive growth.
5
The Lore
Its GLP-1 weight-loss and diabetes drugs triggered a global shortage so severe that pharmacies worldwide couldn't keep up — patients were rationing doses and governments took notice.
6
The Giveaway
Mounjaro. Zepbound. Trulicity. The Indiana drugmaker whose tirzepatide made the whole world want to talk about their waistline.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving LLY's Business? Latest 10-Q Breakdown

AI-extracted from ELI LILLY & Co's 10-Q filed 2026-04-30 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Eli Lilly reported $19.8B in Q1 2026 revenue, +56% YoY, driven by Mounjaro and Zepbound which represent 65% of total revenue; net income surged 168% to $7.4B.

Biggest Revenue Drivers

Total revenue: $19.8B+56% YoY

Oncology$2.3B+16% YoY

Verzenio growth offset by modest decline in other oncology products.

Immunology$1.2B+10% YoY

Modest growth across Taltz and other immunology products.

Collaboration and Other Revenue$1.3B+19% YoY

Revenue from Boehringer Ingelheim collaboration and other licensing arrangements.

Largest Expense Items

Cost of sales$3.6B+61% YoY

Increased proportionally with volume growth; gross margin as percent of revenue declined 0.6 percentage points due to lower realized prices.

Research and development$3.5B+28% YoY

Continued investments in early and late-stage portfolio development.

Marketing, selling, and administrative$2.9B+19% YoY

Higher promotional efforts supporting ongoing and planned product launches.

Acquired in-process research and development$0.6B-63% YoY

Lower than prior year which included Scorpion Therapeutics acquisition; 2026 includes Ventyx acquisition ($977M IPR&D).

Margins: Gross margin decreased 0.6 percentage points to 81.9% of revenue, primarily driven by lower realized prices from government pricing agreements, NRDL listing in China, and customer mix shifts. Operating leverage from higher volumes was offset by pricing pressures.

Watch Items from the Filing

Mounjaro and Zepbound account for 65% of Q1 2026 revenue; significant dependence on cardiometabolic product portfolio creates concentration risk. Volume fluctuations in these products could have disproportionate impact on results.
U.S. government pricing agreements finalized in Q1 2026 include Medicare GLP-1 Bridge program (discounted obesity medicines through Dec 31, 2027) and lower Medicaid prices. Impact of expanded access and uptake is unknown; broader U.S. policy efforts to align pricing with international benchmarks remain uncertain.
Jardiance revenue includes $250M one-time benefits in Q1 2026 vs. $370M in Q1 2025 from collaboration with Boehringer Ingelheim. Right to receive up to $660M in potential sales-based milestones in 2026.
Pending acquisition agreements with potential payouts of approximately $12B at closing; also $850M unfunded venture capital commitments. Capital expenditures expected to be meaningfully higher in near term to support manufacturing expansion.
Emgality patent litigation: April 2026 Federal Circuit opinion reversed trial court's invalidation finding and remanded to district court; company recognized charge in Q1 2026 and is assessing next steps. IRA selected Trulicity and Verzenio for Medicare government-set pricing effective 2028.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$19.8B

Net Income

Q1 2026

$7.4B

Free Cash Flow

Q1 2026

$5.3B

Operating Margin

Q1 2026

44.7%

D/E Ratio

Q1 2026

1.39

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+44.7% YoY

$65.18BFY 2025

FY22 $28.54BFY23 $34.12BFY24 $45.04BFY25 $65.18B

Net Income

+94.9% YoY

$20.64BFY 2025

FY22 $6.24BFY23 $5.24BFY24 $10.59BFY25 $20.64B

EPS (Diluted)

+96.0% YoY

$22.95FY 2025

FY22 $6.90FY23 $5.80FY24 $11.71FY25 $22.95

Total Assets

+42.9% YoY

$112.48BFY 2025

FY22 $49.49BFY23 $64.01BFY24 $78.72BFY25 $112.48B

Total Debt

+26.3% YoY

$42.50BFY 2025

FY22 $16.24BFY23 $25.23BFY24 $33.64BFY25 $42.50B

Op. Cash Flow

+90.7% YoY

$16.81BFY 2025

FY22 $7.59BFY23 $4.24BFY24 $8.82BFY25 $16.81B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$65.18B +44.7%	$45.04B +32.0%	$34.12B +19.6%	$28.54B +0.8%	$28.32B +15.4%	$24.54B
Net Income	$20.64B +94.9%	$10.59B +102.1%	$5.24B -16.1%	$6.24B +11.9%	$5.58B -9.9%	$6.19B
EPS (Diluted)	$22.95 +96.0%	$11.71 +101.9%	$5.80 -15.9%	$6.90 +12.7%	$6.12 -9.9%	$6.79
Total Assets	$112.48B +42.9%	$78.72B +23.0%	$64.01B +29.3%	$49.49B +1.4%	$48.81B +4.7%	$46.63B
Total Debt	$42.50B +26.3%	$33.64B +33.4%	$25.23B +55.3%	$16.24B -3.8%	$16.88B +1.7%	$16.60B
Operating Cash Flow	$16.81B +90.7%	$8.82B +108.0%	$4.24B -44.1%	$7.59B +3.0%	$7.37B +13.3%	$6.50B

AI Insight: LLY Financial Trends

LLY posts accelerating revenue growth and expanding net margins despite rising debt levels.

• Revenue grew 75% from Q2 2024 ($11.3B) to Q1 2026 ($19.8B), with Q1 2026 marking highest quarterly sales.

• Net income surged 149% from Q2 2024 ($2.97B) to Q1 2026 ($7.40B); net margin expanded to 37.3% in latest quarter.

• Operating cash flow averaged $4.1B over last four quarters, peaking at $8.8B in Q3 2025.

⚠ Total debt increased 50% from Q2 2024 ($28.9B) to Q1 2026 ($43.4B); debt-to-equity ratio rose from 2.13x to 1.39x.

⚠ Q3 2024 net income dropped to $970M (8.5% margin) amid operational volatility; consistency warrants monitoring.

AI Insight: LLY Ratio Trends

LLY has sustained 40%+ operating margins and 45%+ ROIC since Q2 2025, while deleveraging meaningfully from 2.44x D/E to 1.39x.

• Operating margin stabilized at 41–45% from Q2 2025 onward, up from 28% baseline in Q1 2025; NPM similarly at 32–37%.

• ROIC expanded from 25.5% (Q1 2025) to 47.5% (Q1 2026), sustaining 43–48% range last three quarters.

• Debt-to-equity ratio fell 43% from peak 2.44x (Q1 2025) to 1.39x (Q1 2026), lowest in trailing period.

⚠ ROE volatility remains high: 70–124% quarterly despite margin consistency, signaling potential leverage or equity structure fluctuations.

⚠ Q3 2024 spike in leverage (2.19x) and margin collapse (13.9% OpMargin) suggests prior operational or financial disruption; recurrence risk unclear.

Get alerted when LLY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ELI LILLY & Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LLY

LILLY ENDOWMENT INC
$84.5B91,896,978 sh
BlackRock, Inc.
$61.1B66,380,842 sh
VANGUARD CAPITAL MANAGEMENT LLC
$49.1B53,361,774 sh
PNC FINANCIAL SERVICES GROUP, INC.
$47.2B51,328,908 sh
STATE STREET CORP
$32.8B35,610,002 sh
FMR LLC
$24.2B26,341,031 sh
Capital Research Global Investors
$22.7B24,632,647 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$19.3B20,977,027 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.5B20,191,864 sh
Capital World Investors
$14.4B15,621,813 sh

Fund	Value	Shares
LILLY ENDOWMENT INC	$84.5B	91,896,978
BlackRock, Inc.	$61.1B	66,380,842
VANGUARD CAPITAL MANAGEMENT LLC	$49.1B	53,361,774
PNC FINANCIAL SERVICES GROUP, INC.	$47.2B	51,328,908
STATE STREET CORP	$32.8B	35,610,002
FMR LLC	$24.2B	26,341,031
Capital Research Global Investors	$22.7B	24,632,647
VANGUARD PORTFOLIO MANAGEMENT LLC	$19.3B	20,977,027
GEODE CAPITAL MANAGEMENT, LLC	$18.5B	20,191,864
Capital World Investors	$14.4B	15,621,813

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LLY on your watchlist

Track score changes the day ELI LILLY & Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LLY a good stock to buy?

13F Pro's AI-powered analysis of ELI LILLY & Co (LLY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LLY are available on the LLY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LLY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LLY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ELI LILLY & Co's investment landscape.